Shanghai Huace Navigation Technology (300627.SZ) forecasts a net profit of 565 million to 585 million yuan for the year, an increase of 25.8% to 30.25% year-on-year.
Huace Navigation (300627.SZ) disclosed the 2024 annual performance forecast, the company is expected to net profit attributable to the listed company shareholders...
Shanghai Huace Navigation Technology (300627.SZ) disclosed its annual performance forecast for 2024. The company expects a net profit attributable to shareholders of the listed company of 5.65 billion to 5.85 billion yuan, a year-on-year increase of 25.80% to 30.25%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is expected to be 5.03 billion to 5.23 billion yuan, a year-on-year increase of 35.10% to 40.47%.
During the reporting period, the company actively expanded the industry applications of its products and solutions, and saw significant growth in operating income in related business areas such as resources, public utilities, and geographic information. The company focused its resources on aggressively expanding into overseas markets, with continued rapid growth in overseas regional operating income. The company continued to increase its investment in research and development, build core technological barriers, enhance the company's product competitiveness, and help the company rapidly expand its business in various industry markets.
Related Articles

Shandong Gold Phoenix (603586.SH): The CRH380D-type EMU brake pads have passed small batch trial use.

Qinglong Pipes Industry Group (002457.SZ) signed a contract for the 55.2671 million yuan water supply trunk line project.

CSPC Innovation Pharmaceutical (300765.SZ) subsidiary Siriuskiov monoclonal antibody injection III phase clinical trial obtained top-line analysis data.
Shandong Gold Phoenix (603586.SH): The CRH380D-type EMU brake pads have passed small batch trial use.

Qinglong Pipes Industry Group (002457.SZ) signed a contract for the 55.2671 million yuan water supply trunk line project.

CSPC Innovation Pharmaceutical (300765.SZ) subsidiary Siriuskiov monoclonal antibody injection III phase clinical trial obtained top-line analysis data.

RECOMMEND

Super Central Bank Week Arrives! Japan Leads With A Rate Hike As Developed Economies End The Rate‑Cut Cycle, Will The Fed Cut Alone Next Year?
16/12/2025

What Guidance Does The Economic Work Conference Offer For Cross‑Year Market Direction?
16/12/2025

Trade Surplus Tops One Trillion USD: New Challenges For China’s Foreign Trade | Instant Commentary
16/12/2025


